-
Bosutinib, sold
under the
brand name Bosulif, is a
small molecule BCR-ABL and src
tyrosine kinase inhibitor used for the
treatment of
chronic myelogenous...
-
Bosutinib's activity was
first described in 2001 and it was
disclosed as an Abl
kinase inhibitor in 2003. At
first it was
believed that
bosutinib was...
-
approved in
South Korea for
people resistant to or
intolerant of imatinib.
Bosutinib received US FDA and EU
European Medicines Agency approval on 4 September...
- BCR::ABL1 TKI
Generation Imatinib First-generation Dasatinib, Nilotinib,
Bosutinib Second-generation Ponatinib,
Asciminib Third-generation...
-
injectables such as the EpiPen. On
September 4, 2012, the FDA
approved bosutinib (Bosulif) for
chronic myelogenous leukemia (CML), a rare type of leukemia...
-
available inhibitors to
treat CML are imatinib, dasatinib, nilotinib,
bosutinib and ponatinib.
Gastrointestinal stromal tumors (GIST) are
known to withstand...
-
Utidelone L01EA01
Imatinib L01EA02
Dasatinib L01EA03
Nilotinib L01EA04
Bosutinib L01EA05
Ponatinib L01EA06
Asciminib L01EB01
Gefitinib L01EB02 Erlotinib...
- VEGFR1/VEGFR2/VEGFR3/PDGFRB/c-KIT
Pfizer Small molecule 2012
Renal cell
carcinoma Bosutinib Bcr-Abl / SRC
Pfizer Small molecule 2012
Chronic myelogenous leukemia...
- (INN)
Borofax bortezomib (USAN)
Boruzu Bosatria bosentan (INN)
Bosulif bosutinib (USAN, INN)
botiacrine (INN)
Botox Boudreaux's Butt
Paste boxidine (INN)...
-
Other tyrosine kinase inhibitor drugs that are in
clinical trials include bosutinib, bafetinib, Saracatinib(AZD-0530), XLl-999, KX01 and XL228. HSP90 inhibitor...
